These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36609003)

  • 1. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
    Seibert TM; Garraway IP; Plym A; Mahal BA; Giri V; Jacobs MF; Cheng HH; Loeb S; Helfand BT; Eeles RA; Morgan TM
    Eur Urol; 2023 Mar; 83(3):241-248. PubMed ID: 36609003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
    Shi Z; Platz EA; Wei J; Na R; Fantus RJ; Wang CH; Eggener SE; Hulick PJ; Duggan D; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Xu J
    Eur Urol; 2021 Mar; 79(3):419-426. PubMed ID: 33257031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.
    Xu J; Resurreccion WK; Shi Z; Wei J; Wang CH; Zheng SL; Hulick PJ; Ross AE; Pavlovich CP; Helfand BT; Isaacs WB
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):422-430. PubMed ID: 35347252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
    Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
    Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
    Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.
    Mahal BA; Gerke T; Awasthi S; Soule HR; Simons JW; Miyahira A; Halabi S; George D; Platz EA; Mucci L; Yamoah K
    Eur Urol Oncol; 2022 Feb; 5(1):18-29. PubMed ID: 34446369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression.
    Xu J; Shi Z; Wei J; Na R; Resurreccion WK; Wang CH; Sample C; Han M; Zheng SL; Cooney KA; Helfand BT; Isaacs WB
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):749-754. PubMed ID: 35149774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
    Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of genetic markers in the management of prostate cancer.
    Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
    Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
    J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val.
    Giri VN; Ruth K; Hughes L; Uzzo RG; Chen DY; Boorjian SA; Viterbo R; Rebbeck TR
    BJU Int; 2011 Feb; 107(3):466-70. PubMed ID: 20735386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.
    Darst BF; Wan P; Sheng X; Bensen JT; Ingles SA; Rybicki BA; Nemesure B; John EM; Fowke JH; Stevens VL; Berndt SI; Huff CD; Strom SS; Park JY; Zheng W; Ostrander EA; Walsh PC; Srivastava S; Carpten J; Sellers TA; Yamoah K; Murphy AB; Sanderson M; Crawford DC; Gapstur SM; Bush WS; Aldrich MC; Cussenot O; Yeager M; Petrovics G; Cullen J; Neslund-Dudas C; Kittles RA; Xu J; Stern MC; Kote-Jarai Z; Govindasami K; Chokkalingam AP; Multigner L; Parent ME; Menegaux F; Cancel-Tassin G; Kibel AS; Klein EA; Goodman PJ; Drake BF; Hu JJ; Clark PE; Blanchet P; Casey G; Hennis AJM; Lubwama A; Thompson IM; Leach R; Gundell SM; Pooler L; Xia L; Mohler JL; Fontham ETH; Smith GJ; Taylor JA; Eeles RA; Brureau L; Chanock SJ; Watya S; Stanford JL; Mandal D; Isaacs WB; Cooney K; Blot WJ; Conti DV; Haiman CA
    Eur Urol; 2020 Sep; 78(3):316-320. PubMed ID: 32409115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.
    Na R; Ye D; Qi J; Liu F; Lin X; Helfand BT; Brendler CB; Conran C; Gong J; Wu Y; Gao X; Chen Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
    Asian J Androl; 2016; 18(4):525-9. PubMed ID: 27140652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
    Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
    JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
    Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
    Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
    Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
    Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
    Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Markers in Prostate Cancer Decision Making.
    Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
    Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.